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Abstract
The transcription factor ZBED6 acts as a repressor of Igf2 and affects directly or 
indirectly the transcriptional regulation of thousands of genes. Here, we use gene 
editing in mouse C2C12 myoblasts and show that ZBED6 regulates Igf2 exclu-
sively through its binding site 5′-GGCTCG-3′ in intron 1 of Igf2. Deletion of this 
motif (Igf2ΔGGCT) or complete ablation of Zbed6 leads to ~20-fold upregulation of 
the IGF2 protein. Quantitative proteomics revealed an activation of Ras signaling 
pathway in both Zbed6−/− and Igf2ΔGGCT myoblasts, and a significant enrichment 
of mitochondrial membrane proteins among proteins showing altered expression in 
Zbed6−/− myoblasts. Both Zbed6−/− and Igf2ΔGGCT myoblasts showed a faster growth 
rate and developed myotube hypertrophy. These cells exhibited an increased O2 
consumption rate, due to IGF2 upregulation. Transcriptome analysis revealed ~30% 
overlap between differentially expressed genes in Zbed6−/− and Igf2ΔGGCT myotubes, 
with an enrichment of upregulated genes involved in muscle development. In con-
trast, ZBED6-overexpression in myoblasts led to cell apoptosis, cell cycle arrest, 
reduced mitochondrial activities, and ceased myoblast differentiation. The similari-
ties in growth and differentiation phenotypes observed in Zbed6−/− and Igf2ΔGGCT 
myoblasts demonstrates that ZBED6 affects mitochondrial activity and myogenesis 
largely through its regulation of IGF2 expression. This study adds new insights how 
the ZBED6-Igf2 axis affects muscle metabolism.
K E Y W O R D S
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1 |  INTRODUCTION
The ZBED6 transcription factor is unique to placental mam-
mals and has evolved from a domesticated DNA transposon lo-
cated in the first intron of ZC3H11A, a zinc-finger protein with 
RNA-binding capacity.1,2 ZBED6 was identified as a repressor 
of insulin-like growth factor 2 (IGF2) expression following the 
identification of a mutation in IGF2 intron 3 in domestic pigs.1,3 
This mutation disrupts a ZBED6 binding site and leads to a three-
fold increase in the IGF2 mRNA expression in pig skeletal mus-
cle, which in turn results in increased muscle mass and reduced 
subcutaneous fat deposition. We have previously reported that 
ZBED6 has thousands of putative binding sites in human and 
mouse genomes, with a strong enrichment in the vicinity of tran-
scription start sites (TSS) of genes involved in development and 
transcriptional regulation.1,4-6 However, it is still unknown which 
of these genes, besides Igf2, are true functional targets of ZBED6. 
Silencing of Zbed6 expression in mouse C2C12 myoblasts using 
small interfering RNA (siRNA) resulted in differential expres-
sion of about 700 genes, including a three-fold upregulation 
of Igf2 mRNA.4 IGF2 is an essential growth factor in skeletal 
muscle development and has a role in the initiation of myoblast 
differentiation.7 Recently, we have developed Zbed6−/− and Igf2 
knock-in mice, the latter carrying the pig mutation at the ZBED6 
binding site. These mice exhibited increased body weight and 
skeletal muscle growth.8 However, the molecular mechanism 
how ZBED6 affects muscle growth has not been fully investi-
gated. Particularly, the interaction between ZBED6 and Igf2 
during myogenesis, and to which extent phenotypic changes as-
sociated with altered ZBED6 expression is mediated through its 
interaction with the IGF2 locus has hitherto not been studied.
In recent years, the genome editing technique based on the 
microbial Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) 
nucleases, has become the most efficient method to knockout 
a gene of interest or manipulate a specific site in mammalian 
cells.9,10 We employed this technology to explore the sig-
nificance of ZBED6-Igf2 interaction in the mouse myoblast 
C2C12 cell line that has the ability to differentiate and form 
myotubes.11 In the present study, we generated two models 
of engineered C2C12 cells, a Zbed6 knockout and a deletion 
of the ZBED6 binding site in an Igf2 intron. The genetically 
modified C2C12 cells were induced to differentiate, followed 
by whole transcriptome analysis, mass spectrometry (MS)-
based quantitative proteomics and detailed functional charac-
terizations of myoblast proliferation and myotube formation.
2 |  MATERIALS AND METHODS
2.1 | Cell culture
Mouse myoblast C2C12 cells were obtained from ATCC 
(CRL-1772), and it is a subclone of the previously established 
mouse myoblast cell line.11 The cells were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) with 2 mM l-
glutamine, 1 mM sodium pyruvate, and 4.5 g/L of glucose 
(ATCC 30-2001), supplemented with 10% (v/v) heat-inac-
tivated fetal bovine serum (FBS) and penicillin (0.2 U/mL)/
streptomycin (0.2 μg/mL)/l-glutamine (0.2 μg/mL) (Gibco) 
at 37°C in a 5% CO2 humidified atmosphere. Differentiation 
was induced by replacing FBS with 2% horse serum (Gibco). 
The differentiation medium was changed every 48  hours. 
The differentiated myotubes were collected by adding 0.05% 
Trypsin-EDTA (Gibco) for 1 minute at 37°C, which was suf-
ficient to detach the mature myotubes from the plate.
2.2 | Genome editing
The coding sequence of Zbed6 and its binding site in Igf2 
were targeted in C2C12 cells using CRISPR/Cas9 tools. 
Two specific guide RNAs (gRNA) for Zbed6 and one for 
Igf2 were designed using the CRISPRdirect tools.12 The 
gRNAs sequences were cloned into the Cas9 expressing 
plasmid pSpCas9(BB)-2A-GFP (PX458), (Addgene plasmid 
#48138) and co-transfected with linear hygromycin marker 
(Clontech) into C2C12 cells at passage number 5. Wild-type 
(WT) cells were transfected with empty pSpCas9(BB)-2A-
GFP plasmid and linear hygromycin. Transfected cells were 
kept under selective medium for 2 weeks. Single-cell clones 
were screened for a 2.5  kb deletion in Zbed6 using prim-
ers flanking the targeted site (Figure 1A). The Igf2 targeted 
clones were screened using primers flanking the targeted 
site, followed by Sanger sequencing of individual clones.
2.3 | Immunofluorescence staining
Cells were cultured in an 8-well slide chamber (BD Falcon) 
overnight to around 60-70% confluence. The cells were 
washed with PBS and fixed with 4% (v/v) paraformaldehyde 
for 10 minutes at room temperature. The fixed cells were per-
meabilized with 0.25% (v/v) Triton X-100 and then blocked for 
non-specific binding with 2% (w/v) BSA in PBS. The primary 
antibodies for myogenin and myosin heavy chain (Santa Cruz 
Biotechnology) were diluted 1:500 in PBS containing 1% (w/v) 
BSA and incubated with the cells overnight. Cells were washed 
three times with PBS and then incubated with Alexa Flour-
labeled secondary antibodies. DAPI was used as counter stain-
ing. Slides were analyzed using a confocal microscope (Zeiss 
LSM 700).
2.4 | Real-time quantitative PCR
Total RNA was extracted from cells using the RNeasy 
Mini kit (Qiagen), including the DNase I treatment. The 
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High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) was used to generate cDNA from the extracted 
RNA. Quantitative PCR (qPCR) analysis was performed 
using ABI MicroAmp Optical 384-well Reaction plates on an 
ABI 7900 real-time PCR instrument (Applied Biosystems). 
The qPCR was performed using TaqMan Gene Expression 
(A)
(C)
(E)
(G)
(I) (J)
(H)
(F)
(D)
(B)
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Assays that consisted of forward and reverse primers with 
TaqMan minor groove binder (MGB) probe for each gene 
(Zbed6: Mm04178798_s1, Igf2: Mm00439564_m1, 18S: 
Mm03928990_g1, Applied Biosystems); 18S and was used 
as housekeeping gene. For Myog and the validated differen-
tially expressed (DE) genes, the forward and reverse primers 
(Table S6) were mixed with SYBR Green Gene Expression 
Master Mix (Applied Biosystems) in 10 μL of total reaction 
volume.
2.5 | Immunoblot analysis
Total protein lysates were prepared using RIPA lysis buffer 
containing protease inhibitors (Complete Ultra Tablets, 
Roche). Equal amounts of total lysates were separated by 
SDS-PAGE (4-15%, Bio-Rad) and transferred to PVDF mem-
branes (Millipore). StartingBlock buffer (Thermo Scientific) 
was used to block the membrane before the primary anti-
ZBED6 antibody (1:1000) was added.5 Proteins were visual-
ized and detected by the Odyssey system (LI-COR).
2.6 | Stable isotope labeling with amino 
acids in cell culture
C2C12 cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM) for Stable Isotope Labeling with Amino 
acids in Cell culture (SILAC) (Thermo Fisher Scientific) 
supplemented with 10% dialyzed fetal bovine serum (FBS, 
MWCO 10  kDa; Thermo Fisher Scientific), 100  U/mL of 
penicillin (Thermo Fisher Scientific), 100  μg/mL of strep-
tomycin (Thermo Fisher Scientific), 0.25 μg/mL of ampho-
tericin B (Thermo Fisher Scientific) and light isotopic labels 
l-arginine-HCl and l-lysine-2 HCl or heavy isotopic labels 
13C6, 15N4 l-arginine-HCl (Arg-10) and 13C6, 15N2 L-lysine-2 
HCl (Lys-8) (Thermo Fisher Scientific). Cells were kept in a 
humidified atmosphere with 5% CO2 at 37°C. To avoid con-
tamination of light amino acids, sub-culturing was performed 
using Cell dissociation buffer (Thermo Fisher Scientific) in-
stead of trypsin. Isotopic incorporation was checked using 
a script in R as previously described13 after approximately 
five cell divisions to confirm complete (>95%) labeling. 
Arginine-to-proline conversion was assessed by calculating 
the percentage of heavy proline (Pro-6) containing peptides 
among all identified peptides, and kept at <5%. Confluent 
(~80%) cells were washed five times with PBS, and incubated 
12 hours in serum-free medium. Medium was collected, cen-
trifuged and filtered through a 0.2 μm filter. Protein concen-
tration was measured with a Coomassie (Bradford) assay kit 
(Thermo Fisher Scientific). Cells were harvested and lysates 
prepared using M-PER mammalian protein extraction reagent 
(Thermo Fisher Scientific), and protein concentration was 
measured using a bicinchoninic acid (BCA) protein assay kit 
(Thermo Fisher Scientific). Heavy and light cell lysates or 
media (40 μg each of cell lysate, 170 μg each of medium) 
were mixed 1:1. Mixed media were subsequently concen-
trated through spin columns with a cutoff of 3 kDa (Vivaspin, 
Sartorius). Mixed proteins were separated on a 4%-20% 
Mini-PROTEAN TGX precast gel (Bio-Rad, Hercules, CA). 
Each gel lane was cut into 10 separate pieces, and proteins 
were reduced in-gel with 10 mM DTT in 25 mM NH4HCO3, 
thereafter, alkylated with 55 mM iodoacetamide in 25 mM 
NH4HCO3, and finally digested with 17 ng/μL sequencing-
grade trypsin (Promega) in 25 mM NH4HCO3 using a slightly 
modified in-gel digestion protocol.14 The produced peptides 
were eluted from the gel pieces using 1% (v/v) formic acid 
(FA) in 60% (v/v) acetonitrile, dried down in a vacuum cen-
trifuge (ThermoSavant SPD SpeedVac, Thermo Scientific), 
and finally dissolved in 1% (v/v) FA. The experiments were 
run in at least triplicate, of which at least one was reciprocal 
(reverse labeling).
2.7 | Liquid chromatography and mass 
spectrometry
Peptide samples were desalted using Stage Tips (Thermo 
Fisher Scientific) according to the manufacturer's protocol, 
and subsequently dissolved in 0.1% (v/v) FA. Samples were 
separated by RP-HPLC using a Thermo Scientific nLC-
1000 with a two-column setup; an Acclaim PepMap 100 
F I G U R E  1  Knockout of Zbed6 or its binding site in Igf2 alter the growth of myoblasts. A, Schematic description of Zbed6 targeting using 
CRISPR/Cas9. Red scissors indicate the targeted sites of Zbed6 using two gRNAs. Blue arrows indicate the location of the PCR primers that were 
used for genotyping of the KO clones. B, Schematic description of the targeted ZBED6 binding sequences in Igf2 (bold). The scissor indicates 
the cleavage site using specific gRNA sequences (yellow) adjacent to the PAM sequences (blue). Black arrows indicate Igf2 promoters, red boxes 
are the coding sequences of Igf2. C, PCR screening of Zbed6 KO clones. D, Immunoblot validation of Zbed6−/− clones, the Igf2ΔGGCT clone and 
WT cells, NSB: non-specific band. E, Real-time measurements of cell growth (mean ± SEM) of WT C2C12 cells (black) and Zbed6−/− clones 
(red) (n = 3). F, Cell growth of two Igf2-mutant clones (red) and WT cells (black). G, Cell growth measurement of WT C2C12 cells at different 
passages (P5, P12, and P20) and WT cells transfected with Cas9 reagents without gRNA (WT Cas9). H, Quantitative PCR analysis of the Igf2 
mRNA expression after transient expression of ZBED6-GFP in WT cells, Zbed6−/− and Igf2ΔGGCT cells. I, Quantitative PCR analysis of the Zbed6 
mRNA expression and after transient expression of GFP (Control) or ZBED6-GFP (ZBED6-OE) constructs in myoblasts. J, Immunoblot validation 
of ZBED6-GFP overexpression in C2C12 cells. Graph shows the fold changes (mean ± SEM) compared to WT control cells. ns = non significant, 
**P < .01, ***P < .001, Student's t test
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(2 cm × 75 μm, 3 μm particles, Thermo Fisher Scientific) pre-
column was connected in front of an EASY-Spray PepMap 
RSLC C18 reversed phase column (50 cm × 75 μm, 2 μm 
particles, Thermo Fisher Scientific) heated to 35°C, run-
ning solvent A (H2O and 0.1% (v/v) FA). A gradient of 
2-40% solvent B (acetonitrile and 0.1% (v/v) FA) was 
run at 250  nL/min over a period of 3  hours. The eluted 
peptides were analyzed on a Thermo Scientific Orbitrap 
Fusion Tribrid mass spectrometer, operated at a Top Speed 
data-dependent acquisition scan mode, ion-transfer tube 
temperature of 275°C, and a spray voltage of 2.4 kV. Full 
scan MS spectra (m/z 400-2000) were acquired in profile 
mode at a resolution of 120 000 at m/z 200, and analyzed in 
the Orbitrap with an automatic gain control target of 2.0e5 
and a maximum injection time of 100 ms Ions with an in-
tensity above 5.0e3 were selected for collision-induced dis-
sociation fragmentation in the linear ion trap at a collision 
energy of 30%. The linear ion trap automatic gain control 
target was set at 1.0e4 with a maximum injection time of 
40 ms, and data were collected at centroid mode. Dynamic 
exclusion was set at 60 seconds after the first MS1 of the 
peptide. The system was controlled by Xcalibur software 
(version 3.0.63.3, Thermo Scientific). Instrument quality 
control was monitored using the Promega 6x5 LC-MS/MS 
Peptide Reference Mix (Promega) before and after each 
MS experiment run, and analyzed using PReMiS software 
(version 1.0.5.1, Promega).
2.8 | Mass spectrometric data analysis
Data analysis of raw files was performed using MaxQuant 
software (version 1.5.6.5) and the Andromeda search en-
gine,15,16 with cysteine carbamidomethylation as a static 
modification and Arg-10, Lys-8, methionine oxidation, 
and protein N-terminal acetylation as variable modifica-
tions. First search peptide MS1 Orbitrap tolerance was set 
to 20 ppm. Iontrap MS/MS tolerance was set to 0.5 Da. The 
re-quantify option was enabled to get ratios where only one 
isotope pattern was found. Match between runs was also 
enabled, to identify peptides where only MS1 data were 
available. Minimum label ratio count was set to 1, and the ad-
vanced ratio estimation option was enabled. Peak lists were 
searched against the UniProtKB/Swiss-Prot Mus musculus 
proteome database (UP000000589, version 2016-01-12) 
with a maximum of two trypsin miscleavages per peptide. 
The contaminants database of MaxQuant was also utilized. A 
decoy search was made against the reversed database, where 
the peptide and protein false discovery rates were both set to 
1%. Only proteins identified with at least two peptides of at 
least seven amino acids in length were considered reliable. 
The peptide output from MaxQuant was filtered by remov-
ing reverse database hits, potential contaminants and proteins 
only identified by site (PTMs). Intensity values were first 
normalized using variance stabilization method, adjusted 
for batch effect and fitted to linear model.17,18 The empiri-
cal Bayes moderated t-statistics and their associated P-values 
were used to calculate the significance of DE proteins.19 
The P-values were corrected for multiple testing using the 
Benjamini-Hochberg procedures.20 The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository with the data-
set identifiers PXD012757, PXD012758, PXD012769, and 
PXD012789.
2.9 | RNA sequencing
Myoblasts or the collected myotubes were washed in PBS 
and total RNA was extracted using the RNeasy Mini kit 
(QIAGEN). The RNA quality and integrity were meas-
ured with a RNA ScreenTape assay (TapeStation, Agilent 
Technologies). Strand-specific, 3′ end mRNA sequencing 
libraries were generated using QuantSeq 3′ mRNA-Seq 
Library Prep Kit (Lexogen) following the manufacturer's in-
structions. For each sample, 2 µg of total RNA were poly-A 
selected using oligo-dT beads to enrich for mRNA, and the 
RNA-seq libraries were amplified by 12 PCR cycles. The li-
braries were size-selected for an average insert size of 150 bp 
and sequenced as 50  bp paired-end reads using Illumina 
HiSeq. Sequence reads were mapped to the reference mouse 
genome (mm10) using STAR 2.5.1b with default parame-
ters.21 HTSeq-0.6.1 (Python Package)22 was used to generate 
read counts and edgeR (Bioconductor package)23 was used 
to identify (DE) genes using gene models for mm10 down-
loaded from UCSC (www.genome.ucsc.edu). The abundance 
of gene expression was calculated as counts per million 
(CPM) reads. Genes with less than one CPM in at least three 
samples were filtered out. The filtered libraries were nor-
malized using the trimmed mean of M-values (TMM) nor-
malization method.24 P-values were corrected for multiple 
testing using the False Discovery Rate (FDR) approach. The 
DE genes were submitted to The Database for Annotation, 
Visualization and Integrated Discovery (DAVID, v6.8)25 
for gene ontology analysis. All expressed genes in C2C12 
cells were used as background, and the Biological Process 
and KEGG pathway tables were used to identify enriched GO 
terms.
2.10 | Cell growth measurements
Wild-type cells at different passages (P5, P12, and P12), 
WT cells transfected with the Cas9 plasmid (WT-Cas9), 
two Zbed6−/− and two Igf2-mutant clones were seeded in 
24-well plates (10 000 cells per well) in growth media, and 
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were cultured for 6 days with real-time measurement of cell 
density every 12 hour using an IncuCyte instrument (Essen 
Bioscience). The experiments were carried out using biologi-
cal triplicates of each cell line.
2.11 | Cell viability assay
Cells were seeded in 24-well plates (30 000 cells/well) and 
let to attach. A day after, the cells were transfected with 
GFP (control) or ZBED6-GFP overexpressing constructs 
(ZBED6-OE). At 24 hours post transfection, the cells were in-
cubated with growth media containing 10% (v/v) PrestoBlue 
(Invitrogen). The reduction of PrestoBlue reagent was meas-
ured on a Tecan Sunrise Plate Reader at four time points post 
incubation (10 minutes, 30 minutes, 2 hours, and 4 hours), 
with the following parameters: bottom-read fluorescence 
(excitation 560 nm, emission 590 nm).
2.12 | Cell cycle analysis
C2C12 cells transiently expressing ZBED6-GFP or GFP 
were analyzed for cell cycle profile using Click-iT EdU flow 
cytometry assay kit (Invitrogen) and FxCycleTM violet stain 
(Invitrogen) for total DNA staining. Cells were incubated 
with EdU for 2 hours according to the manufacturer's instruc-
tions before fixation and DNA staining. Cells were analyzed 
on an LSR Fortessa (BD Biosciences), and results were ana-
lyzed using the FACSDiva software (BD Biosciences).
2.13 | Cell apoptosis
C2C12 cells were harvested and fixed with 4% PFA (not per-
meabilized), and controls were fixed and permeabilized with 
Cytofix/Cytoperm solution (BD Biosciences) before stain-
ing with V450-Annexin-V (BDBiosciences) and/or DRAQ7 
(Biostatus). Cells were stained with V450-Annexin-V and 
DRAQ7 according to the manufacturer's protocol. Cells were 
incubated for 15-30  minutes at RT in dark. Samples were 
analyzed on a BD LSRFortessa flow cytometer using the BD 
FACSDiva software. Viable cells were Annexin-V negative 
and DRAQ7 negative (AnnV-, PI-) staining, while cells in 
early apoptosis were Annexin-V positive and DRAQ7 nega-
tive. Cells in late-apoptosis/necrosis were Annexin-V posi-
tive and DRAQ7 positive.
2.14 | MitoTracker Red and JC-1 staining
C2C12 cells were stained for active mitochondria by 50nM 
MitoTracker Red FM (Invitrogen) for 30  minutes. After 
washing, the cells were either fixed for confocal imaging 
by a Zeiss 780 confocal microscope or directly examined 
for MitoTracker Red intensity using a FACSCalibur flow 
cytometer (BD Biosciences). Mitochondrial membrane po-
tential of C2C12 cells was semiquantitatively determined by 
the fluorescent probe JC-1 (4  μM, 30  minutes incubation, 
Sigma-Aldrich). After careful washing, the cells were im-
aged by confocal microscope and the fluorescence of JC-1 
aggregates at hyperpolarized membrane potential (585 nm) 
was quantified by Image J.
2.15 | Oxygen consumption and 
extracellular acidification rates
The oxygen consumption rate (OCR) and extracellular acidi-
fication rate (ECAR) were determined using the Extracellular 
Flux Analyzer XFe96 (Seahorse Bioscience). Cells were 
cultured in 96-well plates (Seahorse Biosciences) in nor-
mal culture medium for 24-48  hours. After culture, assays 
were performed in XF assay medium (Seahorse Biosciences) 
set to pH 7.4 and supplemented with 25 mM glucose. OCR 
and ECAR were measured during the last 30  minutes of 
the 1 hour incubation in XF assay medium, which was fol-
lowed by the injection of inhibitors of the electron trans-
port chain, 5  μmol/L rotenone and 5  μmol/L antimycin A, 
to inhibit the mitochondrial respiration. The remaining OCR 
was considered as non-mitochondrial respiration. To calcu-
late the mitochondrial respiration, non-mitochondrial OCR 
was subtracted from the total OCR. Data were normalized to 
cell number in the wells and presented as pmol/min/10 000 
cells. Recombinant mouse IGF2 (R&D Systems, MN, USA), 
5-40  ng/mL was supplemented to the culture medium for 
24 hours before measurement.
3 |  RESULTS
3.1 | Efficient deletion of Zbed6 and its 
binding site in Igf2
In order to explore to which extent phenotypic changes as-
sociated with altered expression of ZBED6 is due to its in-
teraction with the Igf2 locus, we established two genetically 
engineered C2C12 cell lines, one with complete Zbed6 inac-
tivation and the other with a deletion of the ZBED6 binding 
site in the first intron of the Igf2 gene (chr7:142,664,244-
142,664,249, mmu10) (Figure  1A,B). The CRISPR/Cas9 
method was used to delete almost the entire coding sequence 
(2.5 kb out of 2.9 kb) of Zbed6 in C2C12 cells (Figure 1A). 
We genotyped 150 clones using multiplex PCR (Figure 1C) 
and found that 10% of the clones were untargeted, while 90% 
were targeted with at least one gRNA. Of these clones, 22% 
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showed a frameshift in one allele, 74% showed a 2.5 kb dele-
tion of ZBED6 in a single allele and 4% of the clones showed 
a 2.5 kb deletion in both alleles.
The ZBED6 binding motif 5′-GGCTCG-3′ in Igf2 intron 
1 was targeted using a gRNA that cleaves between the C and 
T nucleotides (Figure 1B). PCR screening of C2C12 clones 
revealed several clones with deletions at this site, ranging in 
size from 4 to 120 nucleotides. One of the clones showed 
a four-nucleotide deletion (GGCT) of the binding motif in 
both alleles. We named this clone Igf2ΔGGCT and used it for 
all downstream analysis together with the Zbed6−/− clones; 
a second clone (Igf2Δ120bp) was used to confirm the effect 
on cell growth (see below). The expression of the ZBED6 
protein in the Zbed6−/− and Igf2ΔGGCT clones was evaluated 
by immunoblot analysis, which revealed complete ablation 
of ZBED6 expression in Zbed6−/− clones and normal expres-
sion in Igf2ΔGGCT cells in comparison to WT C2C12 cells 
(Figure 1D).
3.2 | Both Zbed6−/− and Igf2ΔGGCT myoblasts 
exhibit faster cell growth and massive 
upregulation of Igf2 expression
The real-time measurement of growth rate showed that both 
Zbed6−/− and Igf2ΔGGCT/Igf2Δ120bp clones grow faster than 
the WT (Cas9) cells (Figure 1E,F); the WT (Cas9) cells here 
refer to WT cells treated with CRISPR/Cas9 reagents without 
gRNA and kept at similar selection conditions as the targeted 
cells. In order to explore the effect of this condition on cell 
growth, we measured the growth rate of WT (Cas9) vs the 
WT C2C12 cells at early (P5), middle (P12), and late (P20) 
cell passages. The WT (Cas9) had similar growth rate as the 
WT C2C12 cells at early and middle passage, while the late 
passage C2C12 cells grew slower (Figure 1G).
Expression analysis using quantitative reverse transcrip-
tase PCR (RT-qPCR) revealed a more than 30-fold upregula-
tion of Igf2 mRNA when ZBED6 was deleted or its binding 
site in Igf2 was disrupted (Figure 1H). To verify that the in-
creased expression of Igf2 in Zbed6−/− and Igf2ΔGGCT cells, 
indeed, was caused by the loss of ZBED6 or its binding site, 
we generated and validated an expression construct that pro-
duces a ZBED6-GFP fusion protein (Figure 1I,J). We rein-
troduced ZBED6 into the Zbed6−/− and Igf2ΔGGCT clones by 
transient overexpression of ZBED6-GFP (ZBED6-OE). The 
GFP construct was used as control. qPCR analysis confirmed 
an efficient overexpression of Zbed6 in WT, Zbed6−/−, and 
Igf2ΔGGCT cells (Figure 1I). The overexpression of Zbed6 in 
WT cells resulted in a significant 60% downregulation of 
Igf2 mRNA. Interestingly, reintroduction of ZBED6-GFP 
in Zbed6−/− clones significantly downregulated the ele-
vated expression of Igf2, while no changes were observed 
when ZBED6-GFP was overexpressed in Igf2ΔGGCT clones 
(Figure 1H). These results imply that ZBED6 represses Igf2 
expression exclusively through interaction with its binding 
site in Igf2 intron 1.
3.3 | Zbed6−/− and Igf2ΔGGCT myoblasts 
develop myotube hypertrophy with improved 
contractile properties after differentiation
The differentiation profile of Zbed6−/− and Igf2ΔGGCT myo-
blasts was assessed by time-lapse microscopy (Supporting 
Information Video) and immunofluorescence staining of 
myotubes using myogenin and myosin heavy chain (MyHC) 
antibodies (Figure  2A). The differentiation of Zbed6−/− 
and Igf2ΔGGCT myoblasts resulted in formation of hyper-
trophic myotubes post 4  days of differentiation induction 
(Figure 2A), with significant increase in the differentiation 
index and myotube diameter in Zbed6−/− and Igf2ΔGGCT myo-
tubes in comparison to WT cells (Figure 2B,C). The length 
of the hypertrophic myotubes was significantly shorter than 
the WT myotubes (Figure 2D). This was associated with in-
creased MyHC and myogenin expression in Zbed6−/− and 
Igf2ΔGGCT myotubes (Figure 2E,F).
3.4 | Quantitative SILAC proteomic and 
transcriptomic analyses of Zbed6−/− and 
Igf2ΔGGCT myoblasts
To determine the possible transcriptional targets of ZBED6 
during myogenesis, we performed both transcriptomic and 
mass spectrometry (MS)-based quantitative proteomic analy-
ses of Zbed6−/−, Igf2ΔGGCT, and WT myoblasts. Differentially 
regulated genes/proteins and pathways were analyzed with a 
special focus on genes that showed differential expression in 
both Zbed6−/− and Igf2ΔGGCT myoblasts in order to explore 
to which extent the observed changes in gene expression in 
Zbed6−/− clones are secondary effects due to increased IGF2 
expression.
The SILAC-MS technique was used to quantitate the 
changes in the total proteome of the mutant myoblasts. 
Quantitation analysis using MaxQuant identified around 
4000 proteins in each cell line with at least two unique pep-
tides detected in each replicate. The DE analysis of SILAC 
data showed 312 and 855 DE proteins in Zbed6−/− medium 
and lysate fractions, respectively, and 220 and 350 DE pro-
teins in Igf2ΔGGCT medium and lysate fractions, respectively 
(P < .05, after Benjamini-Hochberg correction for multiple 
testing), (Figure S1, Table  S1). The transcriptome analysis 
of Zbed6−/−, Igf2ΔGGCT, and WT myoblasts identified around 
12 000 expressed genes with at least one read count per mil-
lion (cpm). DE analysis of transcriptome data revealed ~3000 
DE genes in Zbed6−/− and ~2500 in Igf2ΔGGCT myoblasts 
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(Table S2). We integrated the SILAC and RNA-seq data in 
order to explore the correlation between changes in mRNA 
and protein expression, to gain further understanding of how 
the ZBED6-Igf2 axis affects myoblasts. We detected 381 and 
196 genes to be DE in both SILAC and RNA-seq in Zbed6−/− 
and Igf2ΔGGCT myoblasts, respectively. Moreover, we found 
a significant positive correlation between DE genes and pro-
teins in Zbed6−/− (r = .49) and Igf2ΔGGCT (r = .55) myoblasts 
(Figure 3A). Strikingly, the dramatic upregulation of Igf2 was 
detected in both Zbed6−/− and Igf2ΔGGCT myoblasts at both 
the transcriptome and proteome level (Figure 3A).
In order to distinguish between the DE genes caused by 
ZBED6 inactivation and those that are secondary due to Igf2 
upregulation, we calculated the overlap between DE genes and 
proteins in both Zbed6−/− and Igf2ΔGGCT myoblasts. This anal-
ysis showed 56 shared DE proteins in Zbed6−/− and Igf2ΔGGCT 
cells, and 325 DE proteins unique to Zbed6−/− myoblasts, while 
140 was unique to Igf2ΔGGCT cells (Figure  3B, left). KEGG 
F I G U R E  2  Zbed6−/− and Igf2ΔGGCT myoblasts develop hypertrophic myotubes. A, Immunofluorescence staining of 4 days differentiated WT, 
Zbed6−/− and Igf2ΔGGCT myotubes using anti-myogenin antibody (green), anti-myosin-heavy chain (MyHC) antibody (red),and DAPI (blue). B, 
Differentiation index of WT, Zbed6−/−, and Igf2ΔGGCT myotubes, calculated as the percentage of nuclei in myotubes to the total number of nuclei 
in the same field.40 C and D, Diameter and length of myotubes. E, The relative intensity of MyHC staining in the differentiated myotubes. F, qPCR 
analysis of Myogenin expression in myotubes, the graph presents the relative expression to WT myoblast (mean ± SEM), **P < .01, ***P < .001, 
Student's t test
(A)
(B) (C) (D) (E) (F)
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pathway analysis of those 56 shared DE proteins revealed a sig-
nificant enrichment of proteins involved in extra cellular matrix 
(ECM)−receptor interaction, and the MAPK and RAS signal-
ing pathways (Figure 3B, right). Interestingly, the cellular com-
ponent analysis of DE proteins unique to Zbed6−/− myoblasts 
showed a significant enrichment for mitochondrial membrane 
proteins (Figure 3C), while a similar analysis for the 56 shared 
DE proteins and the DE proteins unique to Igf2ΔGGCT myoblasts 
showed an enrichment for extracellular matrix proteins, and not 
for mitochondrial terms (Figure S2).
Our previous ChIP-seq analysis for ZBED6 identified 
thousands of putative target genes in C2C12 myoblasts.1,4 
Here, we combined the SILAC, RNA-seq, and ChIP-seq data 
to find out functional targets for ZBED6. The previously de-
scribed ChIP-seq peaks in C2C12 cells were associated with 
about 3000 genes, that is, about 15% of the genes in the mouse 
genome. As many as 1001 of the about 4000 proteins (25%) 
detected in the SILAC analysis corresponded to a gene asso-
ciated with a ZBED6 ChIP-seq peak. This highly significant 
overrepresentation (P <  .001) is consistent with the notion 
F I G U R E  3  SILAC proteomic and transcriptome analyses of Zbed6−/− and Igf2ΔGGCT myoblasts. A, Expression of identified proteins and 
genes by SILAC and RNA-seq data in Zbed6−/− (left) and Igf2ΔGGCT (right) myoblasts. The values are presented as log fold change (logFC) to WT 
cells and colored based on the FDR < 0.05 values. B, Intersection of DE proteins in both Zbed6−/− and Igf2ΔGGCT myoblasts (left), KEGG pathway 
analysis of the shared 56 DE proteins (right). C, GO analysis of the 325 DE proteins in Zbed6−/− myoblasts. GeneRatio indicates the number of 
genes found in each term as a proportion of the total number of examined genes. D, Intersection of DE proteins in Zbed6−/− myoblasts and putative 
ZBED6 targets that are expressed in C2C12 cells and detected by SILAC and RNA-seq (left), the fold changes of genes/proteins with ZBED6 
binding sites (right). E, GO analysis of upregulated genes/proteins in Zbed6−/− myoblasts with ZBED6 binding sites
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that ZBED6 binds open chromatin.4 Since 25% of the pro-
teins detected by SILAC corresponded to a gene associated 
with a ChIP-seq peak it is expected that 25% (95) of the 381 
genes detected as DE both at the mRNA and protein level due 
to chance only. We found 98 genes in our data (Figure 3D, 
left). This implies that we cannot draw any firm conclusion 
on true ZBED6 targets in mouse C2C12 cells, other than the 
well-established Igf2 locus, based on these data. In fact, Igf2 
is the gene showing the most striking DE gene between WT 
and Zbed6−/− cells (Figure  3D, right). However, five other 
genes, highlighted in Figure  3D, showed a striking upreg-
ulated expression after silencing of the ZBED6 repressor, 
suggesting that they may be functional targets. The gene 
ontology (GO) analysis of the transcripts with significant 
upregulation in Zbed6−/− myoblasts and associated with 
ChIP-seq peaks showed a significant enrichment for proteins 
involved in cellular response to insulin stimulus (Figure 3E). 
These genes include Insulin-Like Growth Factor 1 Receptor 
(Igf1r), Phosphoinositide-3-Kinase Regulatory Subunit 1 
(Pik3r1), and Ectonucleotide pyrophosphatase phosphodies-
terase 1 (ENPP1), a negative modulator of insulin receptor 
(IR) activation.
3.5 | ZBED6 modulates transcriptional 
regulation of differentiated myotubes partially 
through IGF2 signaling
To investigate the possible role of the ZBED6-Igf2 axis on 
transcriptional regulation during myogenesis, we performed 
transcriptome analyses of Zbed6−/−, Igf2ΔGGCT and WT 
cells after differentiation into myotubes. First, we analyzed 
the DE genes in WT myoblasts vs myotubes to explore the 
overall transcriptional changes during myotube formation. 
The counting of aligned reads using the STAR tool21 identi-
fied ~12 000 expressed genes in myoblasts with at least one 
read count per million (cpm) (Figure S3A). The expression 
of ~3900 genes was found to be changed significantly, with 
2200 upregulated and 1700 downregulated genes after differ-
entiation into myotubes (P < .05, after Benjamini-Hochberg 
correction for multiple testing), (Figure S3B). GO analysis 
of upregulated genes revealed a significant enrichment of 
cell adhesion, muscle proteins and muscle contraction genes, 
while the downregulated genes were enriched for cell cycle 
and mitotic nuclear division categories (Figure S3C).
Transcriptome analysis comparing WT and Zbed6−/− 
cells after differentiation identified 2673 DE genes (log fold 
change > 0.5; P < .05, after Benjamini-Hochberg correction 
for multiple testing), with 1243 upregulated and 1430 down-
regulated genes. Furthermore, 2630 genes showed a signifi-
cant differential expression in the comparison of Igf2ΔGGCT 
and WT cells after differentiation, with 1278 upregulated and 
1352 downregulated in mutant cells (Table S4). The dissection 
of the DE genes based on the direction of the change revealed 
a highly significant (Chi-square test, P  <  .001) 30% over-
lap between DE genes in Zbed6−/− and Igf2ΔGGCT myotubes 
(Figure 4A).
The expression of Igf2 is known to be upregulated during 
myoblast differentiation.7 In this study, we detected the same 
pattern as Igf2 was upregulated 100-fold after differentiation 
of WT cells (Figure 4B). Furthermore, the Igf2 mRNA ex-
pression was upregulated 500-fold in Zbed6−/− and Igf2ΔGGCT 
myotubes in comparison to WT myoblast and six-fold in 
comparison to WT myotubes (Figure 4B). Interestingly, this 
upregulation of Igf2 expression was accompanied with a sig-
nificant but modest increase in the expression of the endog-
enous Zbed6 mRNA (Figure 4C), which indicates a positive 
correlation between Igf2 and Zbed6 expression.
The GO analysis of the upregulated genes in both Zbed6−/− 
and Igf2ΔGGCT myotubes exhibited a striking enrichment 
of muscle-specific genes (Figure  4D, left). This included 
genes for myosin heavy and light chains (Myl1, Myl2, Myh1, 
Myh2, Myh7, and Myh8), troponins (Tnnt1, Tnnt3, Tnnc1, 
and Tnni2), myomesins (Myom1 and Myom2), alpha actinin 
(Actn2 and Actn3), leiomodin (Lmod2 and Lmod3), titin (Ttn) 
and myoglobin (Mb). In contrast, genes involved in cell divi-
sion and cell cycle regulation such as cyclins (Ccnb1, Ccna2, 
and Ccnb2), were enriched among downregulated genes in 
both Zbed6−/− and Igf2ΔGGCT myotubes (Figure  4D, right). 
The expression of genes belonging to these GO categories 
is presented as logCPM values in myoblast and myotubes 
(Figure  4E,F). The results demonstrate a remarkable shift 
in their expression before and after differentiation, and how 
these differences are enhanced in Zbed6−/− and Igf2ΔGGCT 
myotubes.
3.6 | ZBED6 overexpression impairs 
myoblast differentiation
The role of ZBED6 in myogenesis was further investigated by 
overexpressing ZBED6 (ZBED6-OE) in C2C12 myoblasts 
and then induce differentiation. Immunofluorescence staining 
against myogenin and MyHC revealed poor differentiation of 
ZBED6-OE myoblasts, with a marked reduction in cells ex-
pressing myogenin and myosin (Figure 5A). This observation 
was in stark contrast to the myotube hypertrophy observed in 
Zbed6−/− C2C12 cells after differentiation (Figure 2A). We 
performed RNA-seq analysis of ZBED6-OE and control cells 
after 72 hours of differentiation. The bioinformatic analysis of 
differentiated myoblasts revealed 1560 downregulated genes 
and 1157 upregulated genes (log fold change > 0.5; P < .05, 
after Benjamini-Hochberg correction for multiple testing) in 
ZBED6-OE vs control cells (Figure S4). The most affected 
genes in response to ZBED6-OE included downregulation of 
Igf2, myogenin (Myog), and myosin heavy chain 3 (Myh3) 
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(Figure 5B, Figure S4). The GO analysis of downregulated 
genes showed a significant enrichment of muscle-specific 
genes, while the upregulated genes were primarily related 
to cell cycle regulation and cell division (Table 1), thus the 
opposite trend compared with Zbed6−/− cells. As many as 
463 genes were significantly downregulated in differenti-
ated ZBED6-OE myoblasts and significantly upregulated in 
Zbed6−/− myotubes (Figure 5C). These represent about 40% 
of the upregulated genes in Zbed6−/− myotubes. We exam-
ined these genes and the corresponding pathways in more 
detail. The GO analysis revealed a striking enrichment in 
muscle-specific categories (Table S5). Among the enriched 
KEGG pathways, we found cardiac muscle contraction, hy-
pertrophic cardiomyopathy (HCM), and calcium, insulin and 
F I G U R E  4  Transcriptome analysis of Zbed6−/− and Igf2ΔGGCT myotubes. A, Intersection of upregulated and downregulated DE genes in 
Zbed6−/− myotubes (red) vs Igf2ΔGGCT myotubes (blue). B and C, The expression analysis of Igf2 (B) and Zbed6 (C) mRNA in WT, Zbed6−/−, and 
Igf2ΔGGCT myoblasts and myotubes as counts per million (CPM). D, GO analysis of upregulated (left) and downregulated (right) DE genes in both 
Zbed6−/− and Igf2ΔGGCT myotubes. Bars show multiple testing corrected P-value for enriched GO categories. E, Heatmap of muscle-specific genes 
that were found in muscle contraction GO categories. Expression values are presented as logCPM and color-scaled from blue (low-expression) to 
red (high-expression). Each column represents an individual sample of Zbed6−/− (KO1 and KO2), Igf2ΔGGCT, and WT groups. F, Heatmap of genes 
that were found in cell cycle and mitotic nuclear division GO categories
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AMPK signaling (Table S5). We examined the genes present 
in the AMPK and insulin signaling pathways and compared 
their expression in Zbed6−/−, Igf2ΔGGCT, and ZBED6-OE 
cells after differentiation. Interestingly, the key components 
of these pathways were found to be upregulated in Igf2ΔGGCT 
myotubes as well (Figure 5D). For instance, the expression 
of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit beta (Pik3cb), glycogen synthase 1 (Gys1) and AMP-
activated protein kinase alpha2 (Prkaa2), beta2 (Prkab2), 
and gamma3 (Prkag3) subunits were found to be upregulated 
in Zbed6−/− and Igf2ΔGGCT myotubes, and downregulated in 
ZBED6-OE differentiated cells (Figure  5D). Activation of 
F I G U R E  5  Overexpression of 
ZBED6 impairs myotube differentiation. A, 
Immunofluorescence staining of myogenin 
and MyHC in 72 hours differentiated 
myoblasts transiently overexpressing 
ZBED6 (ZBED6-OE). (Scale bar: 50 μm). 
B, Log fold change in the expression of 
Myog, Igf2, and Myh3 mRNA in control 
and ZBED6-OE differentiated myoblasts 
in comparison to un-differentiated 
control myoblasts (***FDR < 0.001). C, 
Intersection of upregulated DE genes in 
Zbed6−/− myotubes (red) vs downregulated 
DE genes in ZBED6-OE differentiated 
myoblasts (green). D, Heatmap of genes 
found in the AMPK and insulin signaling 
pathways
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the PI3K pathway and its downstream targets plays a cen-
tral role in myogenesis. Interestingly, Prkaa2, Prkab2, and 
Prkag3, all upregulated in Zbed6−/− and Igf2ΔGGCT myotubes, 
encode the AMPK α2, β2, and γ3 subunits. These subunits 
form a specific isoform of AMPK that shows tissue-specific 
expression in white skeletal muscle.26 The results imply that 
the interaction between ZBED6-Igf2 has an essential role in 
muscle development and influences muscle metabolism.
3.7 | Overexpression of ZBED6 in non-
differentiated C2C12 cells results in reduced 
cell viability and cell cycle arrest
Since deletion of ZBED6 promotes cell proliferation and 
myogenesis, we investigated whether the overexpression of 
ZBED6 causes the opposite effect. Unfortunately, we did not 
succeed in our attempts to establish a stable myoblast cell 
line overexpressing ZBED6, suggesting that overexpression 
may be lethal in C2C12 cells, which is consistent with the re-
sults of a previous study.27 Therefore, we measured cell via-
bility after transient overexpression of ZBED6 (ZBED6-OE) 
in C2C12 cells. We found a significant reduction in cell vi-
ability in ZBED6-OE cells in comparison to control cells 
(Figure S5). The cell apoptosis analysis using flow cytometry 
revealed a significant reduction in the number of live cells in 
ZBED6-OE (Figure 6A). Moreover, cell cycle analysis using 
flow cytometry displayed a significant difference in the pro-
portion of cells in different cell cycle phases, in which 82% 
of ZBED6-OE cells appeared to be in the G0/G1 phase and 
10% in the S-phase, whereas the corresponding proportions 
in control cells were 58% and 35%, respectively (Figure 6B). 
These phenotypic changes in ZBED6-OE myoblasts were in 
complete agreement with the RNA-seq analysis that revealed 
a significant enrichment of genes involved in cell cycle and 
cell division processes among the downregulated genes after 
ZBED6-OE in proliferating myoblasts (Table 2). Out of 98 
downregulated cell cycle-related genes, 21 were previously 
identified as putative direct targets of ZBED61,4 (Figure 6C). 
Some of the putative direct targets with essential role in cell 
cycle regulation were validated by qPCR (Figure S6). These 
included the genes for E2f1 and E2f2, members of the E2f 
family that has an essential role in regulating cell prolifera-
tion and controls the transition from G1 to S phase.28 There 
was a striking upregulation of genes involved in immune de-
fense after ZBED6-OE in proliferating myoblasts (Table 2). 
These results suggest that ZBED6 inhibits proliferation and 
promotes immune defense in C2C12 cells.
3.8 | Changes in mitochondrial activity 
in response to altered ZBED6 expression 
in myoblasts
The strong correlation between mitochondrial biogenesis and 
aerobic metabolism, on the one hand, and mesenchymal stem 
cell differentiation, on the other hand, is well established.29-31 
The marked increase in mitochondrial activity that occurs 
during mesenchymal differentiation is driven by the tran-
scription factor PGC-1α, and IGF2 has been suggested to 
participate in this process.32 Moreover, RNA-seq and SILAC 
proteomic analyses showed a significant enrichment for 
mitochondrial membrane proteins among DE proteins in 
Zbed6−/− myoblasts (Figure 3C). These observations encour-
aged us to look closer at mitochondrial activities in response 
to ZBED6-overexpression or ablation. Flow cytometry anal-
ysis of MitoTracker Red intensity, a dye that labels active 
mitochondria in living cells, indicated a significant reduction 
in mitochondrial mass in ZBED6-OE cells and an increase 
in mitochondria in Zbed6−/− cells, while no change was ob-
served in Igf2ΔGGCT cells (Figure 6D,E). As MitoTracker Red 
labeling only gives a very crude estimate of mitochondrial 
mass and activity, we also stained transiently ZBED6-GFP 
transfected C2C12 cells with JC-1, a probe that gives an es-
timate of the inner mitochondrial membrane potential. These 
experiments demonstrated that ZBED6-GFP overexpressing 
cells displayed lower JC-1 aggregates (red fluorescence) to 
JC-1 monomers (green fluorescence) ratio (Figure  6F,G), 
indicating a decreased mitochondrial membrane potential in 
response to overexpressed ZBED6. Both the MitoTracker 
and JC-1 experiments are in agreement with the SILAC data, 
and suggest an inhibitory role of ZBED6 on mitochondrial 
mass/function. Since both Zbed6−/− and Igf2ΔGGCT myo-
blasts exhibited similar phenotypic characteristics regard-
ing growth and differentiation, we explored another part of 
T A B L E  1  Gene ontology analysis of upregulated and 
downregulated differentially expressed genes in ZBED6-
overexpressing vs control (GFP) myoblasts before and after 
differentiation
Term Count FDR
Downregulated
Muscle contraction 28 2.5 × 10−11
Cell adhesion 75 1.2 × 10−9
Multicellular organism 
development
129 6.6 × 10−9
Cardiac muscle contraction 24 3.1 × 10−8
Skeletal muscle contraction 19 4.3 × 10−8
Upregulated
Cell cycle 127 4.7 × 10−25
Mitotic nuclear division 81 9.3 × 10−24
Cell division 92 1.4 × 10−22
DNA replication 39 7.4 × 10−10
Chromosome segregation 30 1.1 × 10−8
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F I G U R E  6  Overexpression of ZBED6 leads to reduced cell viability, cell cycle arrest, and reduced mitochondrial activity. A, Cell apoptosis 
assay of myoblasts overexpressing ZBED6-GFP fusion protein vs the control myoblasts expressing GFP. B, Cell cycle analysis of myoblasts 
overexpressing ZBED6-GFP fusion protein vs GFP expressing cells. C, The expression of downregulated genes found in cell cycle GO categories 
and containing the consensus ZBED6 binding motif within 1kb of their TSS.1,4 D, MitoTracker Red labeling of ZBED6 transient overexpressing 
(ZBED6-GFP) cells. E, Flow cytometry analysis of the intensity of MitoTracker Red labeling of active mitochondria in WT, ZBED6-
overexpression (ZBED6-OE), Zbed6−/−, and Igf2ΔGGCT cells. F, A representative image of JC-1 aggregates, JC-1 monomer of ZBED6-GFP cells 
to measure the mitochondrial hyperpolarized membrane potentials. G, Quantitation of the fluorescence intensity of JC-1 aggregates (red) in WT 
(GFP-neg) and transient ZBED6-OE (GFP-pos) using ImageJ. (Totally 104 WT and 50 ZBED6-OE cells were quantified from three independent 
experiments.). H, The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined with the Extracellular Flux 
Analyzer XFe96 in C2C12 cells (WT, ZBED6-OE, Zbed6−/−, and Igf2ΔGGCT). Results are means ± SEM for five independent observations. (I) OCR 
and ECAR were determined in C2C12 WT cells supplemented with 5, 10, 20, and 40 ng/ml IGF2 in culture medium. Results were normalized to 
control condition and are means ± SEM for at least six replicates in each condition. *Denotes P < .05 vs WT using one-way ANOVA
(A)
(D)
(F)
(H) (I)
(G)
(E)
(B) (C)
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mitochondrial function in these cells. We analyzed C2C12 
cell mitochondrial oxidation rates (OCR) using the Seahorse 
technique.33 The OCR and extracellular acidification rate 
(ECAR) assay revealed an increased OCR (Figure 6H, left) 
and reduced ECAR in Zbed6−/− and Igf2ΔGGCT myoblasts 
(Figure 6H, right) compared to WT cells. OCR and ECAR 
were unaffected in ZBED6-OE cells (Figure  6H). As both 
Zbed6−/− and Igf2ΔGGCT myoblasts show increased Igf2 ex-
pression, we hypothesized that the increase in respiration 
might be an IGF2 effect. To test this hypothesis, we treated 
cells with recombinant IGF2 and measured the OCR and 
ECAR dose-response in C2C12 WT cells. We found a two-
fold increase in respiration rates at the higher IGF2 concen-
trations (20 and 40 ng/mL IGF2) (Figure 6I, left), while no 
changes were detected in the extracellular acidification rates 
(Figure 6I, right). Thus, it appears that ZBED6 controls myo-
blast mitochondrial biogenesis/activity partially via IGF2.
4 |  DISCUSSION
This study conclusively demonstrates that the interaction 
between ZBED6 and its binding site in Igf2 plays a critical 
role in regulating the development of myogenic cells. This 
conclusion is based on (i) MS quantitative proteomics and 
transcriptomic analyses, (ii) the altered growth rate of myo-
blasts, (iii) effects on myotube formation and maturation, and 
(iv) assessment of mitochondrial activities. Interestingly, the 
disruption of the ZBED6 binding site in Igf2 was sufficient 
to obtain very similar phenotypic effects as observed in the 
Zbed6 knockout demonstrating that the phenotypic effects 
caused by Zbed6 inactivation in myoblast cells are largely 
mediated through the regulation of Igf2 expression.
The initial development of skeletal muscle occurs pre-
natally and involves the proliferation of myoblasts, which 
then exit the cell cycle and start differentiation to form myo-
tubes.34,35 It has been reported that the number of myoblasts 
prenatally greatly influences muscle growth postnatally 
since the number of muscle fibers is fixed at birth.36,37 This 
is of particular interest, since ZBED6 inactivation or disrup-
tion of the interaction between ZBED6 and the binding site 
in Igf2 promotes the proliferation and growth of myoblasts 
(Figure  1E,F). The Zbed6−/− and Igf2ΔGGCT myoblasts had 
a ~30-fold upregulation in the Igf2 mRNA expression. This 
massive increase in Igf2 expression was rescued toward the 
levels found in WT cells when ZBED6 was reintroduced in 
Zbed6−/− myoblasts, while no changes were observed in case 
of Igf2ΔGGCT myoblasts. Thus, ZBED6 represses Igf2 expres-
sion through the binding site located in Igf2 intron 1.
Our results on myoblast differentiation revealed that 
Zbed6−/− and Igf2ΔGGCT myoblasts were prone to develop ma-
ture, hypertrophic and contractile myotubes, with a striking 
increase in the expression of well-known markers of mus-
cle differentiation, Igf2, myogenin and myosin heavy chain 
(MyHC). In contrast, overexpression of ZBED6 blocked 
the differentiation of myoblasts, and the expression of Igf2, 
myogenin and MyHC were greatly downregulated. These 
phenotypic changes are in agreement with our transcrip-
tome data that revealed a significant ~30% overlap between 
DE genes in Zbed6−/− and Igf2ΔGGCT myotubes (Figure 4A). 
Gene ontology analysis of the upregulated genes in common 
between Zbed6−/− and Igf2ΔGGCT myotubes demonstrated a 
significant enrichment of muscle-specific categories, includ-
ing genes encoding myosin heavy and light chains, troponins, 
titin, myomesins, alpha actinin, leiomodin, and myoglobin. 
Interestingly, ~40% of the upregulated DE genes in Zbed6−/− 
myotubes were found to be downregulated in differentiated 
C2C12 cells after overexpressing ZBED6. The GO analysis 
of those genes showed an enrichment in muscle-specific cat-
egories very similar to what we found among upregulated 
genes in Zbed6−/− myotubes.
Stable Isotope Labeling with Amino acids in Cell culture 
quantitative proteomic analysis of mutant myoblasts revealed 
a significant enrichment of mitochondrial membrane proteins 
exclusively among the DE proteins found in Zbed6−/− but not 
Igf2ΔGGCT myoblast (Figure 3C). This observation was con-
firmed by the decreased mitochondrial membrane potential in 
response to ZBED6 overexpression (Figure 6D-G). However, 
the assessment of mitochondrial respiration rate indicated a 
positive correlation between oxygen consumption rate and 
the amount of IGF2 protein in myoblasts. This was con-
cluded by the consistent changes in oxygen consumption in 
Zbed6−/− and Igf2ΔGGCT myoblasts, and after the addition of 
recombinant IGF2 to the growth medium of wild-type myo-
blasts. Our findings fit well with what has been reported in 
literature about the essential role of mitochondrial activities 
T A B L E  2  Gene ontology analysis of upregulated and 
downregulated differentially expressed genes in ZBED6-
overexpressing vs control (GFP) proliferating myoblasts
Term Count FDR
Downregulated
mRNA processing 63 3.7 × 10−4
DNA replication initiation 13 6.3 × 10−4
Cell cycle 98 1.2 × 10−3
DNA replication 34 1.6 × 10−3
Mitotic nuclear division 54 8.0 × 10−3
Upregulated
Cellular response to 
interferon-beta
21 1.5 × 10−9
Immune system process 61 5.3 × 10−8
Innate immune response 54 7.7 × 10−7
Defense response to virus 34 1.7 × 10−6
Oxidation-reduction process 86 4.8 × 10−3
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in proliferation and differentiation of myoblasts. For in-
stance, respiration-deficient human myoblasts were grow-
ing slower than control cells, exhibited low ATP synthesis 
and demonstrated sever deficiency in myotube formation.38 
Furthermore, it has been indicated that the basal mitochon-
drial respiration rate was increased one-fold and the maximal 
respiration increased four-fold in differentiated myotubes.39
We have previously reported that ZBED6 has ~2500 bind-
ing sites all over the genome.1,4 Here we find that the disrup-
tion of only one of these binding sites, located in Igf2 intron 
1, resulted in similar phenotypic changes as observed by com-
plete inactivation of Zbed6 in C2C12 cells. The results sug-
gest that the regulation of IGF2 expression may be the most 
important role of ZBED6 in skeletal muscle cells, which is 
consistent with the initial observation that a mutation of this 
binding site is causing an altered body composition in pigs 
selected for meat production3 and our recent characterization 
of Zbed6−/− and Igf2 knock-in mice.8 However, ZBED6 is es-
sentially found in all cell types and throughout development, 
so it may interact with other important targets in other cells 
or during other stages of development.
In summary, we have shown that the upregulation of Igf2 
expression obtained either by ZBED6 ablation or the deletion 
of its binding site in intron one of Igf2, has an essential role in 
modulating the metabolism of myogenic cells and promotes 
differentiation of myoblast cells partially through increas-
ing respiration rate of the mitochondria. This study provides 
strong support for the notion that the ZBED6-Igf2 axis has an 
essential role for muscle metabolism.
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